共 62 条
- [1] Bagratuni T(2013)Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens Am J Hematol 88 765-770
- [2] Kastritis E(2005)Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma Blood 106 3777-3784
- [3] Politou M(2001)Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management Best Pract Res Clin Haematol 14 401-436
- [4] Roussou M(2013)A case of acquired dysfibrinogenemia in multiple myeloma treated with therapeutic plasma exchange Transfus Apher Sci 48 35-38
- [5] Kostouros E(2009)Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias Br J Haematol 145 151-163
- [6] Gavriatopoulou M(2007)Acquired dysfibrinogenemia caused by monoclonal production of immunoglobulin λ light chain Haematologica 92 e111-e117
- [7] Lonial S(1989)Inhibition of fibrin monomer polymerization by Bence Jones protein in a patient with primary amyloidosis Acta Haematol-Basel 81 160-165
- [8] Waller EK(2020)Acquired dysfibrinogenemia: monoclonal λ-type IgA binding to fibrinogen caused lower functional plasma fibrinogen level and abnormal clot formation Int J Hematol 112 96-104
- [9] Richardson PG(2008)Acquired dysfibrinogenemia secondary to multiple myeloma Acta Haematol-Basel 120 75-81
- [10] Jagannath S(2002)Structure and function of human fibrinogen inferred from dysfibrinogens Int J Hematol 76 352-360